ORPHA:157997
Benign cephalic histiocytosis
Publications
106
46.7th percentile
Trials
0
Interventional, condition-specific
Researchers
475
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare non-Langerhans cell histiocytosis characterized by multiple small yellowish-red or brown papules initially erupting predominantly in the head and neck region. The histopathological hallmark of these eventually self-healing lesions is a dermal proliferation of histiocytes with intracytoplasmic comma-shaped bodies, coated vesicles, and desmosome-like structures. Birbeck granules are absent. The disease typically occurs in young children.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015533
- UMLS:C0347403
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
106 matched papers (46 in last 10 years) Source
- Phenotype characterisedPresent
4 HPO annotations (e.g. Papule; Inflammatory abnormality of the skin; Skin rash) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 69 for broader category histiocytosis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
4
Associated phenotypes · MONDO:0015533
- Papule
- Inflammatory abnormality of the skin
- Skin rash
- Histiocytosis
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
106
106 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
106 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
46 in the last 10 years · high confidence · 46.7th percentile (publications denominator)
Phrase hits: 106 · MeSH hits: 0
Who's working on it?
475
Distinct author names in 106 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Emile JF3 papers · 2022
Research Unit EA4340, Versailles University, Paris-Saclay University, Boulogne, France; Pathology Department, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France;
Papers in Europe PMC - 02
- 03Lange M3 papers · 2023
Department of Dermatology, Venereology, and Allergology, Medical University of Gdansk, Gdansk, Poland.
Papers in Europe PMC - 04Abdel-Wahab O2 papers · 2021
Leukemia Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY;
Papers in Europe PMC - 05Barsky S2 papers · 1985Papers in Europe PMC
- 06Caputo R2 papers · 1993Papers in Europe PMC
- 07Cerio R2 papers · 2005Papers in Europe PMC
- 08Diamond EL2 papers · 2022
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY;
Papers in Europe PMC - 09Donadieu J2 papers · 2021
Research Unit EA4340, Versailles University, Paris-Saclay University, Boulogne, France; Pediatric Hematology, Trousseau Hospital, APHP, Paris, France;
Papers in Europe PMC - 10Duran-McKinster C2 papers · 2006Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 69 trials are registered for histiocytosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
69 interventional trials matched histiocytosis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: histiocytosis
69
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07431060·RECRUITING·Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Conditions: Langerhans Cell Histiocytosis (LCH)·Matched via name phrase
- NCT04943211·RECRUITING·Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Conditions: Histiocytosis·Matched via name phrase
- NCT07728201·NOT YET RECRUITING·Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT05786924·RECRUITING·Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Conditions: Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis · BRAF Gene Mutation·Matched via name phrase
- NCT04943198·RECRUITING·Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Conditions: Histiocytosis·Matched via name phrase
- NCT04943224·RECRUITING·Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Conditions: Histiocytosis·Matched via name phrase
- NCT05997602·RECRUITING·To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Conditions: Langerhans Cell Histiocytosis · LCH·Matched via name phrase
- NCT06712810·RECRUITING·Q702 for the Treatment of Patients With Hematologic Malignancies
Conditions: Hematopoietic and Lymphatic System Neoplasm · Histiocytic Sarcoma · Malignant Histiocytosis · Peripheral T-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT06582745·RECRUITING·Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT07187193·RECRUITING·Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT02670707·RECRUITING·Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Conditions: Langerhans Cell Histiocytosis·Matched via name phrase
- NCT06078969·RECRUITING·Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Conditions: Langerhans Cell Histiocytosis of Bone·Matched via name phrase
- NCT07022834·RECRUITING·Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
Conditions: Langerhans Cell Histiocytosis (LCH)·Matched via name phrase
- NCT07440290·RECRUITING·DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Conditions: Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type·Matched via name phrase
- NCT06902792·ENROLLING BY INVITATION·Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
Conditions: Histiocytosis, Langerhans-Cell·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Benign cephalic histiocytosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Benign cephalic histiocytosis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Benign cephalic histiocytosis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"histiocytosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:04:16.943Z
